10-Q: Outlook Therapeutics Reports Q2 2024 Results, Faces Going Concern Uncertainty Despite Positive European Regulatory Opinion

Outlook Therapeutics reported a significant net loss for the second quarter of 2024 and faces substantial doubt about its ability to continue as a going concern, despite a positive opinion from the European Medicines Agency for its lead product candidate.

Summary

• Outlook Therapeutics reported a net loss of $114.3 million for the three months ended March 31, 2024, and a net loss of $125.5 million for the six months ended March 31, 2024.
• The company's research and development expenses increased significantly, primarily due to costs associated with the NORSE EIGHT clinical trial.
• General and administrative expenses decreased slightly due to reduced professional fees.
• A substantial increase in warrant-related expenses and changes in the fair value of warrant liabilities contributed to the large net loss.
• The company's cash and cash equivalents stood at $47.2 million as of March 31, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern, but believes that existing cash, combined with recent financing and potential warrant exercises, could fund operations through 2025.
• The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for ONS-5010 in March 2024, with a final decision from the European Commission expected in the second quarter of 2024.
• The company is also pursuing regulatory approval in the UK and is working to address CMC issues raised by the FDA in a Complete Response Letter (CRL).

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive news regarding the CHMP opinion and recent financing, the significant net loss, going concern uncertainty, and ongoing legal issues weigh heavily on the overall sentiment. The company faces significant financial challenges and risks, which temper the positive regulatory developments.

Positives

• The European Medicines Agency's CHMP issued a positive opinion for ONS-5010, indicating potential approval in the EU.
• The company successfully raised $55.5 million through a private placement in March 2024.
• The company received confirmation from the FDA that the NORSE EIGHT trial protocol meets the requirements for a second adequate and well-controlled clinical trial.
• The first subject was enrolled in the NORSE EIGHT trial in January 2024, and over 30% of the required subjects have been enrolled to date.
• The company has identified approaches to resolve the CMC comments in the FDA's Complete Response Letter.

Negatives

• The company reported a significant net loss of $114.3 million for the three months ended March 31, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company's research and development expenses increased significantly, primarily due to the NORSE EIGHT clinical trial.
• The company incurred substantial warrant-related expenses and changes in the fair value of warrant liabilities.
• The company is still working to address CMC issues raised by the FDA in the Complete Response Letter.

Risks

• The company's ability to continue as a going concern is uncertain, and additional financing will be needed.
• The company's future operations are dependent on the successful completion of additional financing, regulatory approvals, and market acceptance of its products.
• The company is subject to risks associated with clinical trials, regulatory approvals, and competition from other biotechnology and pharmaceutical companies.
• The company is involved in a securities class action lawsuit, which could result in significant legal fees and costs.
• The company's ability to access cash, cash equivalents, and investments may be threatened by broader financial institution liquidity risk and concerns.

Future Outlook

The company plans to focus on supporting the review of its BLA submission for ONS-5010 with the FDA and preparing for the potential launch of LYTENAVA, if approved. The company anticipates incurring additional losses until it can generate significant sales of ONS-5010 or other product candidates. Management believes that existing cash, combined with recent financing and potential warrant exercises, could fund operations through 2025.

Management Comments

• Management does not believe that the existing cash and cash equivalents as of March 31, 2024, combined with the proceeds from the Syntone private placement in April 2024, are sufficient to fund the Company's operations through one year from the date of this Quarterly Report on Form 10-Q.
• Management is currently evaluating different strategies to obtain the required funding for future operations, including but not limited to, continuing to access capital through at-the-market offering agreements, proceeds from potential licensing and/or marketing arrangements or collaborations with pharmaceutical or other companies, the issuance of equity securities, the issuance of additional debt, and revenues from potential future product sales, if any.
• Management does believe that the existing cash and cash equivalents as of March 31, 2024, combined with $5,000,000 of gross proceeds from the Syntone private placement that closed in April 2024, when combined with the expected proceeds from the full exercise of warrants to purchase shares of common stock (subject to meeting the requirements for calling the associated warrants), would be sufficient to support the Company's operations through 2025.

Industry Context

The company is developing ONS-5010 as an ophthalmic formulation of bevacizumab, aiming to be the first approved product of its kind for retinal indications. This is significant because currently, bevacizumab is used off-label for these conditions. The company's efforts to gain regulatory approval in the US, EU, and UK are aimed at capturing a significant market share by providing a safe and approved alternative to off-label use.

Comparison to Industry Standards

• The company's clinical trial results for ONS-5010, particularly the NORSE TWO trial, showed statistically significant and clinically relevant improvements in visual acuity compared to ranibizumab (LUCENTIS), a standard treatment for wet AMD. Specifically, 41.7% of patients treated with ONS-5010 gained at least 15 letters in BCVA compared to 23.1% with ranibizumab.
• The company's approach of seeking a standard BLA rather than a biosimilar pathway is notable, as it aims to establish ONS-5010 as a unique, approved product rather than a copy of an existing one. This strategy is different from companies pursuing biosimilar approvals for bevacizumab.
• The company's financial situation, with substantial losses and a going concern warning, is not uncommon for clinical-stage biopharmaceutical companies. However, the magnitude of the losses and the uncertainty around future funding are significant concerns.
• The positive opinion from the CHMP is a significant achievement, placing the company in a position to potentially launch in the EU ahead of the US, which is a different trajectory than many US-based biopharma companies.

Corporate Governance

Legal Proceedings

• A securities class action lawsuit was filed against the company and certain of its officers in the United States District Court for the District of New Jersey, alleging violations of the Securities Exchange Act of 1934 related to the company's BLA.

Related Party Transactions

• The company has a joint venture agreement with Syntone PRC, which owns 80% of Beijing Syntone Biopharma Ltd, with the company owning the remaining 20%.
• The company entered into a royalty-free license with Syntone JV for the development, commercialization and manufacture of ONS-5010 in the greater China market.
• The company has a strategic partnership agreement with MTTR, which was terminated effective March 19, 2020. Former principals of MTTR were compensated as consultants and later as employees.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and substantial losses.
• Employees may be impacted by potential workforce reductions if the company is unable to secure additional funding.
• Customers (physicians and patients) may benefit from the potential approval of ONS-5010 as a safe and effective treatment for retinal diseases.
• Creditors face increased risk due to the company's financial instability.
• Suppliers may be impacted by potential changes in the company's operations and spending.

Next Steps

• The company will continue to enroll subjects in the NORSE EIGHT clinical trial, with topline results expected by the end of calendar year 2024.
• The company will work to address the CMC issues raised by the FDA in the Complete Response Letter.
• The company expects a final decision from the European Commission on the MAA for ONS-5010 in the second quarter of 2024.
• The company will continue to pursue regulatory approval in the UK.
• The company will evaluate various strategic opportunities to obtain the required funding for future operations.

Key Dates

Keywords

ONS-5010, LYTENAVA, bevacizumab, wet AMD, retinal diseases, clinical trials, FDA, EMA, CHMP, regulatory approval, biopharmaceutical, going concern, financing, warrants, reverse stock split